CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs.
Lixia WangFei YiLina FuJiping YangSi WangZhaoxia WangKeiichiro SuzukiLiang SunXiuling XuYang YuJie QiaoJuan Carlos Izpisua BelmonteZe YangYun YuanJing QuGuang-Hui LiuPublished in: Protein & cell (2017)
Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with cellular and molecular mechanisms yet to be fully described. Mutations in a number of genes including SOD1 and FUS are associated with familial ALS. Here we report the generation of induced pluripotent stem cells (iPSCs) from fibroblasts of familial ALS patients bearing SOD1 +/A272C and FUS +/G1566A mutations, respectively. We further generated gene corrected ALS iPSCs using CRISPR/Cas9 system. Genome-wide RNA sequencing (RNA-seq) analysis of motor neurons derived from SOD1 +/A272C and corrected iPSCs revealed 899 aberrant transcripts. Our work may shed light on discovery of early biomarkers and pathways dysregulated in ALS, as well as provide a basis for novel therapeutic strategies to treat ALS.
Keyphrases
- amyotrophic lateral sclerosis
- induced pluripotent stem cells
- genome wide
- crispr cas
- single cell
- rna seq
- genome editing
- end stage renal disease
- dna methylation
- copy number
- ejection fraction
- newly diagnosed
- early onset
- small molecule
- peritoneal dialysis
- spinal cord
- high throughput
- case report
- cancer therapy
- drug delivery